In recent weeks, Google has been busy adding AI features to all of its most popular apps. Following Gmail and Chrome, Maps is now the latest service to get a Gemini makeover, with a redesign of the ...

Wegovy and Ozempic maker Novo Nordisk NOVO.B-0.19%decrease; red down pointing triangle filed a lawsuit against Hims & Hers as it seeks a ban on the telehealth provider offering copycat versions of the ...

Novo Nordisk, maker of Wegovy, saw its stock rise 6.5% after the opening bell on Monday. The company and the U.S. Food and Drug Administration threatened legal action against Hims & Hers, over its ...

The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss ...

Hims & Hers on Saturday said it would stop offering its copycat Wegovy weight-loss pill. The decision comes after Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration threatened ...

Greta Kerkhoff, editor in chief of the student newspaper at the University of Colorado at Boulder, was expecting to spend her final year of college working at the paper and completing her journalism ...

New research from scholars, consulting teams, and other experts can give you and your organization the knowledge you need to make sharper strategic decisions. We’ve curated a set of counterintuitive ...

Why go out for dinner when you can make a restaurant-worthy meal at home? Plus, it's undeniably fun to recreate familiar favorites in the comfort of your own kitchen. From an Olive Garden-inspired ...

Apple has updated its App Review Guidelines with multiple new rules, including one targeting the misleading use of other developers’ branding. Here are the details. From time to time, Apple updates ...

Oct 30 (Reuters) - Palantir Technologies (PLTR.O), opens new tab on Thursday sued two of its former senior engineers, accusing them of using the software company's secret information to launch a ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs. By Rebecca Robbins The Food and Drug Administration ...